A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model: Comparative study of two beta-blocking drugs, nipradilol and propranolol

Nephron

Volumn 93, Issue 2, 2003, Pages

  Takamitsu, Yoshihiro ^a   Nakanishi, Takeshi ^a   Nishihara, Futoshi ^a   Hasuike, Yukiko ^a   Izumi, Masaaki ^a   Inoue, Toru ^a   Hiraoka, Keisuke ^a   Itahana, Reiko ^a   Miyagawa, Koji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Blocker; Chronic renal failure; Glomerulosclerosis; Hypertension; Nitric oxide; Proteinuria

Indexed keywords

ARGININE METHYL ESTER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NIPRADILOL; NITRIC OXIDE; PROPRANOLOL; CYCLIC GMP; ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRITE; PROPANOLAMINE DERIVATIVE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; URINARY EXCRETION; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; FISCHER 344 RAT; GLOMERULUS; KIDNEY; KIDNEY DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; URINE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CYCLIC GMP; ENZYME INHIBITORS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; NEPHRECTOMY; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRITES; PROPANOLAMINES; PROPRANOLOL; PROTEINURIA; RATS; RATS, INBRED F344; RENIN;

EID: 0345059993     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068529     Document Type: Article

References (47)

1. Brenner BM: Nephrology forum: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983;23:647-655.
2. Glassock RJ: Focus on proteinuria. Am J Nephrol 1990;10(suppl 1):88-93.
3. Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-380.
4. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
5. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response in renal ablation. Am J Physiol 1981;241:F85-F93.
6. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsh MJ: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989;36:969-977.
7. Lews EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
8. Buhler FR, Laragh JH, Baer E, Vaughan ED, Brunner HR: Propranolol inhibition of renin secretion. N Engl J Med 1972;287:1209-1214.
9. Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE: Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991;303:821-824.
10. Stornello M, Valvo EV, Scapellato L: Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991;58:52-57.
11. Erley CM, Harrer U, Krämer BK, Risler T: Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus ACE inhibitor. Kidney Int 1992;41:1297-1303.
12. Rodríguez-Pérez JC, Losada A, Anabitarta A, Cabrera J, Llobet J, Palop L, Plaza C: Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 1997;283:336-344.
13. Baylis C, Harton P, Engels K: Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1990;1:875-881.
14. Thorup C, Persson AEG: Macula densa derived nitric oxide in regulation of glomerular capillary pressure. Kidney Int 1996;49:430-436.
15. Bachmann S, Mundel P: NO in the kidney: Synthesis, localization and function. Am J Kidney Dis 1994;24:112-129.
16. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
17. Fujihara CK, De Nucci G, Zatz R: Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 1995;5:1498-1507.
18. Reyes AA, Purkerson ML, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992;20:168-176.
19. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, Iaina A: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995;47:1515-1521.
20. 2H-1-benzopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn 1983;262:132-149.
21. Hayashi T, Iguchi A: Nipradilol: A β-adrenoceptor antagonist with nitric oxide-releasing action. Cardiovasc Drug Rev 1998;16:212-235.
22. 2-adrenergic receptor - the role of β-blocker with NO releasing action. Biochem Biophys Res Commun 2001;280:589-594.
23. Koya D, Kikkawa R, Haneda M, Uzu T, Sawada M, Kajiwara N, Sakamoto K, Sugimoto T, Shigeta Y: Nipradilol inhibits rat mesangial cell mitogenesis through the activation of soluble guanylate cyclase. Eur J Pharmacol 1993;245:79-82.
24. Nitta K, Tsutsui T, Uchida K, Eto Y, Natori K, Honda K, Yumura W, Nihei H: Nipradilol inhibits DNA synthesis by regulating nitric oxide synthesis in cultured rat mesangial cells. Eur J Pharmacol 1998;344:107-110.
25. 15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
26. Raji L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984;26:137-143.
27. Newbold KM, Howie AJ, Girling AJ, Kinzaki T, Bryan RL, Carey MP: A simple method for assessment of glomerular size and its use in the study of kidneys in acromegaly and compensatory renal enlargement. J Pathol 1989;158:139-146.
28. Bartholomew B, Hill MJ: The pharmacology of dietary nitrate and the origin of urinary nitrate. Fed Chem Toxicol 1984;22:789-795.
29. Baylis C, Vallance P: Measurement of nitrite and nitrate levels in plasma and urine: What does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 1998;7:59-62.
30. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99:8306-8311.
31. Sakai K, Akima M, Saito K, Saitoh M, Matsubara S: Nicorandil metabolism in rat myocardial mitochondria. J Cardiovasc Pharmacol 2000;35:723-728.
32. MacAllister RJ, Whitley G, Vallance P: Effect of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994;45:737-742.
33. Vallance P, Leone A, Calvar A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
34. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moor WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993;42:221-232.
35. Bouby N, Hassler C, Parvy P, Bankir L: Renal synthesis of arginine in chronic renal failure: In vivo and in vitro studies in rats with 5/6 nephrectomy. Kidney Int 1993;44:676-683.
36. Ingram A, Parbtani A, Thai K, Ly H, Shankland S, Morrissey G, Scholey W: Dietary supplementation with L-arginine limits cell proliferation in the remnant glomerulus. Kidney Int 1996;48:1857-1865.
37. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, Todeschini M, Remuzzi G: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 1999;33:746-753.
38. Garg UC, Hassid H: Inhibition of rat glomerular mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989;257:F60-F66.
39. Meijer AJ, Lamers WH, Chamuleau RAFM: Nitrogen metabolism and ornithine cycle function. Physiol Rev 1990;70:701-748.
40. Hirshberg RR, Zipser RD, Slomowitz LA, Kopple JH: Glucagon and prostaglandins are mediators of amino acid-induced rise in renal hemodynamics. Kidney Int 1988;33:1147-1155.
41. Friedlander G, Blanchet-Benque F, Nitenberg A, Laborie C, Assan R, Amiel C: Glucagon secretion is essential for amino acid-induced hyperfiltration in man. Nephrol Dial Transplant 1990;5:110-117.
42. Ahloulay M, Bouby N, Machet F, Kubrusly M, Coutaud C, Bankir L: Effects of glucagon on glomerular filtration rate and urea and water excretion. Am J Physiol 1992;263:F24-F36.
43. Lortie MJ, Novotny WF, Peterson OW, Vallon V, Malvey K, Mendonca M, Satriano J, Insel P, Thomson SC, Blantz RC: Agmatine, a biological metabolite of arginine: Production, degradation, and functional effects in the kidney of the rat. J Clin Invest 1996;97:413-420.
44. Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA:L-Arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA 1995;92:4552-4556.
45. Ibrahim HN, Hostetter TH: The renin-aldosterone axis in two models of reduced renal mass in the rat. J Am Soc Nephrol 1998;9:72-76.
46. Bretta-Piccoli C, Weidmann P, de Chatel R, Reubi F: Hypertension associated with early stage kidney disease: Complementary roles of circulating renin, the body sodium/volume state and duration of hypertension. Am J Med 1976;61:739-747.
47. Mitas JA, Levy SB, Holle R, Frigon RP, Stone RA: Urinary kallikrein activity in the hypertension of renal parenchymal disease. N Engl J Med 1978;299:162-165.